ReviewCurrent oncology reports2009
Second-line treatment paradigms for diffuse large B-cell lymphomas.
Review in Current oncology reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01466868 (A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.Oncotarget · 2016Trial
- Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Trial
- Lymphoma relapse 1 year or later after immunochemotherapy in DLBCL patients: clinical features and outcome.Clinical and experimental medicine · 2024Article
- TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation.Nature communications · 2020Article
- Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma.International journal of molecular sciences · 2020Article
- Chemotherapy-induced thrombocytopenia and platelet transfusion in patients with diffuse large B-cell lymphoma.Translational cancer research · 2020Article
- Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma.Translational cancer research · 2019Article
- Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression.Translational oncology · 2018Article
- Expression of hypoxia-inducible factor-1a predicts benefit from rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.International journal of clinical and experimental pathology · 2018Article
- VEGFOncotarget · 2017Article
- [Efficacy and prognostic analysis of 98 cases of relapsed/refractory diffuse large B-cell lymphoma treated with second-line regimens].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2017Article
- The prognosis ofThe journal of pathology. Clinical research · 2015Article
- Rituximab purging and maintenance therapy combined with autologous stem cell transplantation in patients with diffuse large B-cell lymphoma.Oncology letters · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent major advances in treating diffuse large B-cell lymphoma with dose-intense regimens and the addition of the anti-CD20 monoclonal antibody rituximab, a significant proportion of patients will experience early treatment failure, partial response, or relapse after initial chemotherapy. For more than 10 years, the standard treatment for chemosensitive relapses has been based on salvage chemotherapy followed by high-dose therapy and autologous stem cell transplantation in selected patients. However, several important questions remain: What is the best salvage regimen? What is the efficacy of rituximab in an era when R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is accepted as standard care for frontline therapy? What are the risk factors in second-line therapy? What is the best treatment when high-dose therapy and autologous stem cell transplantation are not possible? This article reviews all these issues and discusses new biologic therapies, with the knowledge that improvements in outcome may be achieved through a greater understanding of the biologic parameters associated with poorer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.